MCID: DYS011
MIFTS: 38

Dyskinesia of Esophagus

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyskinesia of Esophagus

MalaCards integrated aliases for Dyskinesia of Esophagus:

Name: Dyskinesia of Esophagus 12 15
Esophageal Motility Disorders 55 44 73
Esophageal Motility Disorder 12
Oesophageal Motor Disorder 12
Dyskinesia of Oesophagus 12
Oesophageal Dysmotility 12
Esophageal Dysmotility 12
Esophageal Spasm 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9192
ICD10 33 K22.4
ICD9CM 35 530.5
MeSH 44 D015154

Summaries for Dyskinesia of Esophagus

MalaCards based summary : Dyskinesia of Esophagus, also known as esophageal motility disorders, is related to crest syndrome and esophagitis, eosinophilic, 1, and has symptoms including spasm An important gene associated with Dyskinesia of Esophagus is TEF (TEF, PAR BZIP Transcription Factor). The drugs Methylene blue and Alginic acid have been mentioned in the context of this disorder. Affiliated tissues include thyroid, testes and skin.

Related Diseases for Dyskinesia of Esophagus

Diseases related to Dyskinesia of Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 crest syndrome 32.4 CENPB TOP1 UBTF
2 esophagitis, eosinophilic, 1 30.2 ATP12A ATP4A
3 peptic esophagitis 30.1 ATP12A ATP4A
4 hernia, hiatus 30.1 ATP12A ATP4A
5 scleroderma, familial progressive 30.0 RNPC3 TOP1
6 connective tissue disease 29.7 CENPB RNPC3 TOP1
7 achalasia 10.4
8 fungal esophagitis 10.2 ATP12A ATP4A
9 diclofenac allergy 10.2 ATP12A ATP4A
10 gastroduodenal crohn's disease 10.2 ATP12A ATP4A
11 neonatal candidiasis 10.2 ATP12A ATP4A
12 photoallergic dermatitis 10.2 ATP12A ATP4A
13 squamous papillomatosis 10.2 ATP12A ATP4A
14 toxic megacolon 10.2 ATP12A ATP4A
15 aspiration pneumonitis 10.2 ATP12A ATP4A
16 gastrointestinal neuroendocrine benign tumor 10.2 ATP12A ATP4A
17 granulomatous gastritis 10.2 ATP12A ATP4A
18 esophageal candidiasis 10.2 ATP12A ATP4A
19 gastric neuroendocrine neoplasm 10.2 ATP12A ATP4A
20 acute laryngitis 10.2 ATP12A ATP4A
21 laryngitis 10.2 ATP12A ATP4A
22 duodenitis 10.2 ATP12A ATP4A
23 rumination disorder 10.2 ATP12A ATP4A
24 active peptic ulcer disease 10.2 ATP12A ATP4A
25 congenital disorder of deglycosylation 10.2 ATP12A ATP4A
26 bladder calculus 10.2 ATP12A ATP4A
27 ischemic neuropathy 10.2 ATP12A ATP4A
28 bile reflux 10.2 ATP12A ATP4A
29 capillary disease 10.2 ATP12A ATP4A
30 anismus 10.2 ATP12A ATP4A
31 postsurgical hypothyroidism 10.2 ATP12A ATP4A
32 lymphocytic colitis 10.2 ATP12A ATP4A
33 autonomic neuropathy 10.2
34 clostridium difficile colitis 10.2 ATP12A ATP4A
35 diarrhea 1, secretory chloride, congenital 10.2 ATP12A ATP4A
36 microscopic colitis 10.2 ATP12A ATP4A
37 laryngeal tuberculosis 10.2 ATP12A ATP4A
38 chronic laryngitis 10.2 ATP12A ATP4A
39 eosinophilic gastritis 10.2 ATP12A ATP4A
40 esophagus adenocarcinoma 10.2 ATP12A ATP4A
41 chronic intestinal vascular insufficiency 10.2 ATP12A ATP4A
42 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2 ATP12A ATP4A
43 jejunoileitis 10.2 ATP12A ATP4A
44 pancreatic steatorrhea 10.2 ATP12A ATP4A
45 esophageal varix 10.2 ATP12A ATP4A
46 superior mesenteric artery syndrome 10.2 ATP12A ATP4A
47 duodenal disease 10.2 ATP12A ATP4A
48 gastric lymphoma 10.1 ATP12A ATP4A
49 lower urinary tract calculus 10.1 ATP12A ATP4A
50 myopathy, x-linked, with excessive autophagy 10.1 ATP12A ATP4A

Comorbidity relations with Dyskinesia of Esophagus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dysthymic Disorder
Esophageal Disease Esophagitis
Gastroesophageal Reflux Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Irritable Bowel Syndrome
Ischemic Heart Disease Megaesophagus
Mitral Valve Disease Osteoporosis
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Dyskinesia of Esophagus:



Diseases related to Dyskinesia of Esophagus

Symptoms & Phenotypes for Dyskinesia of Esophagus

UMLS symptoms related to Dyskinesia of Esophagus:


spasm

Drugs & Therapeutics for Dyskinesia of Esophagus

Drugs for Dyskinesia of Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylene blue Approved, Investigational Phase 4,Not Applicable 61-73-4
2
Alginic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-32-7
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73590-58-6 4594
4
Dopamine Approved Phase 4,Phase 3,Not Applicable 51-61-6, 62-31-7 681
5
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
6
Calcium polycarbophil Approved Phase 4 126040-58-2
7
Trimebutine Approved Phase 4 39133-31-8
8
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
9
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3, 138530-94-6 9578005
10
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
11
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
12
mometasone furoate Approved, Vet_approved Phase 4 83919-23-7
13
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
14
Acetylcholine Approved Phase 4,Phase 2,Not Applicable 51-84-3 187
15
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
16
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
17
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1309-42-8
18
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
19 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 14987-04-3
20
Nortriptyline Approved Phase 4,Phase 2,Phase 3 72-69-5 4543
21
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
22
Ethanol Approved Phase 4 64-17-5 702
23
Famotidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 76824-35-6 3325
24
Metoclopramide Approved, Investigational Phase 4,Phase 3,Not Applicable 364-62-5 4168
25
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-45-6, 75614-87-8 774
26
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
27
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
28
Ranitidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 66357-35-5, 66357-59-3 3001055
29
Lithium carbonate Approved Phase 4 554-13-2
30
Asenapine Approved Phase 4 65576-45-6, 85650-56-2 3001386
31
Ziprasidone Approved Phase 4 146939-27-7 60854
32
Clozapine Approved Phase 4 5786-21-0 2818
33
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
34
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
35
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
36
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
39
Clarithromycin Approved Phase 4 81103-11-9 84029
40
Citalopram Approved Phase 4 59729-33-8 2771
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
42
Maleic acid Experimental Phase 4 110-16-7 444266
43 Mosapride Investigational Phase 4,Not Applicable 112885-41-3
44 Rebamipide Investigational Phase 4 90098-04-7
45
Lafutidine Investigational Phase 4,Phase 3 118288-08-7 5282136
46
Polaprezinc Experimental Phase 4 107667-60-7
47 Radiation-Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Coagulants Phase 4,Phase 3,Phase 2,Not Applicable
49 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hemostatics Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 790)
# Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
3 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
4 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Unknown status NCT01882088 Phase 4 Mucofalk
5 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
6 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
7 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
8 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
9 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
10 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
11 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
12 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Unknown status NCT01110811 Phase 4
13 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
14 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
15 Codeine on Pharyngeal and Esophageal Motility Completed NCT03784105 Phase 4 Codeine Phosphate;Siripus simplex
16 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
17 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4 Marinol;Placebo
18 Effect of Citalopram on Reflux Episodes in Healthy Volunteers Completed NCT03746691 Phase 4 Citalopram HCl;Placebos
19 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
20 Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets Completed NCT03037606 Phase 4 Rabelis DDR 50 mg Capsules;Pariet 20 mg Enteric Coated Tablets
21 The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
22 Implementation of PPI Medication PGX Testing Completed NCT02794844 Phase 4 Genotype Guided PPI Dosing
23 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
24 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
25 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Completed NCT02505945 Phase 4 Omeprazole
26 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
27 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
28 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
29 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
30 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
31 Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously Completed NCT00635414 Phase 4 Esomeprazole;Esomeprazole
32 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
33 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4 Esomeprazole
34 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
35 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
36 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
37 Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD Completed NCT00410592 Phase 4 Esomeprazole 40mg;Pantoprazole 40mg;Lansoprazole 30mg
38 Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response Completed NCT00392002 Phase 4 Esomeprazole
39 PPI Sequencing Study Completed NCT00384592 Phase 4 Esomeprazole
40 CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing Completed NCT00354757 Phase 4 rabeprazole
41 Symptom Adapted Therapy in GERD Patients Completed NCT00343161 Phase 4 esomeprazole;Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
42 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) Completed NCT00325676 Phase 4 Pantoprazole
43 Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD Completed NCT00304421 Phase 4 rabeprazole;pantoprazole
44 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole
45 Esomeprazole in PPI Failures - IMPROVE Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
46 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
47 Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI) Completed NCT00251732 Phase 4 Standard dose (once daily) PPI plus low-dose antidepressant;Double dose PPI plus evening placebo;Rabeprazole , placebo, placebo
48 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
49 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
50 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole

Search NIH Clinical Center for Dyskinesia of Esophagus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: esophageal motility disorders

Genetic Tests for Dyskinesia of Esophagus

Anatomical Context for Dyskinesia of Esophagus

MalaCards organs/tissues related to Dyskinesia of Esophagus:

41
Thyroid, Testes, Skin

Publications for Dyskinesia of Esophagus

Articles related to Dyskinesia of Esophagus:

(show top 50) (show all 135)
# Title Authors Year
1
Can Eosinophilic Esophagitis Cause Achalasia and Other Esophageal Motility Disorders? ( 30315308 )
2018
2
Peroral endoscopic myotomy is effective and safe in non-achalasia esophageal motility disorders: an international multicenter study. ( 30105290 )
2018
3
Gender, medication use and other factors associated with esophageal motility disorders in non-obstructive dysphagia. ( 30151201 )
2018
4
Factors predictive of gastroesophageal reflux disease and esophageal motility disorders in patients with non-cardiac chest pain. ( 29848163 )
2018
5
Clinical outcomes five years after POEM for treatment of primary esophageal motility disorders. ( 28664434 )
2018
6
A Procedure for the Automatic Analysis of High-Resolution Manometry Data to Support the Clinical Diagnosis of Esophageal Motility Disorders. ( 28976308 )
2018
7
Esophageal motility disorders: new perspectives from high-resolution manometry and histopathology. ( 29134329 )
2018
8
Factors Determining the Inter-observer Variability and Diagnostic Accuracy of High-resolution Manometry for Esophageal Motility Disorders. ( 29291608 )
2018
9
Ten Initial Cases of Peroral Endoscopic Myotomy for Treatment of Esophageal Motility Disorders at Okayama University Hospital. ( 29674757 )
2018
10
Advances in Management of Esophageal Motility Disorders. ( 29702296 )
2018
11
Factors Determining the Inter-observer Variability and Diagnostic Accuracy of High-resolution Manometry for Esophageal Motility Disorders. ( 29969864 )
2018
12
Management of esophageal motility disorders in children : a review. ( 30024702 )
2018
13
Overlap Between Gastric and Esophageal Motility Disorders: A Contractual Arrangement? ( 30178282 )
2018
14
Peroral endoscopic myotomy (POEM) is effective in treatment of noncardiac chest pain caused by hypercontractile esophageal motility disorders: results of the POEM-HYPE-Study. ( 30296811 )
2018
15
The Role of Botulinum Toxin Injections for Esophageal Motility Disorders. ( 30406479 )
2018
16
Primary Esophageal Motility Disorders: Beyond Achalasia. ( 28665309 )
2017
17
Muscle layer histopathology and manometry pattern of primary esophageal motility disorders including achalasia. ( 27699951 )
2017
18
Characterization of Esophageal Motility Disorders in Children Presenting With Dysphagia Using High-Resolution Manometry. ( 28365899 )
2017
19
Exploratory Research on Latent Esophageal Motility Disorders in Dysphagia Patients. ( 28395277 )
2017
20
Rapid Drink Challenge in high-resolution manometry: an adjunctive test for detection of esophageal motility disorders. ( 27420913 )
2017
21
Esophageal motility disorders. ( 28350732 )
2017
22
High Resolution Manometry Vs Conventional Line Tracing for Esophageal Motility Disorders. ( 28539845 )
2017
23
Esophageal motility disorders-Symptomatic and manometric spectrum in Punjab, northern India. ( 28593551 )
2017
24
Peroral endoscopic myotomy (POEM) for treating esophageal motility disorders. ( 28616407 )
2017
25
Chicago Classification of Esophageal Motility Disorders: Lessons Learned. ( 28730503 )
2017
26
Trends in diagnoses after implementation of the Chicago classification for esophageal motility disorders (V3.0) for high-resolution manometry studies. ( 28881880 )
2017
27
Peroral Endoscopic Myotomy for Treating Achalasia and Esophageal Motility Disorders. ( 26717928 )
2016
28
Lymphocytic Esophagitis in Nonachalasia Primary Esophageal Motility Disorders: Improved Criteria, Prevalence, Strength of Association, and Natural History. ( 27526295 )
2016
29
High-Resolution Manometry Improves the Diagnosis of Esophageal Motility Disorders in Patients With Dysphagia: A Randomized Multicenter Study. ( 26832656 )
2016
30
A pictorial presentation of 3.0 Chicago Classification for esophageal motility disorders. ( 26958977 )
2016
31
Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders: A Pilot Study. ( 27326454 )
2016
32
Chicago Classification of Esophageal Motility Disorders: Applications and Limits in Adults and Pediatric Patients with Esophageal Symptoms. ( 27738966 )
2016
33
A utility of peroral endoscopic myotomy (POEM) across the spectrum of esophageal motility disorders. ( 25847137 )
2016
34
Clinical Application of Esophageal High-resolution Manometry in the Diagnosis of Esophageal Motility Disorders. ( 26631942 )
2016
35
Patterns of esophageal pressure responses to a rapid drink challenge test in patients with esophageal motility disorders. ( 26686375 )
2016
36
Relationship between esophageal clinical symptoms and manometry findings in patients with esophageal motility disorders: a cross-sectional study. ( 26793662 )
2015
37
Inter-observer agreement for diagnostic classification of esophageal motility disorders defined in high-resolution manometry. ( 25185507 )
2015
38
Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases? ( 25212219 )
2015
39
The Chicago Classification of esophageal motility disorders, v3.0. ( 25469569 )
2015
40
Esophageal motility disorders. ( 25965124 )
2015
41
Diagnosis of Esophageal Motility Disorders: Esophageal Pressure Topography vs. Conventional Line Tracing. ( 26032151 )
2015
42
Assessment of bolus transit with intraluminal impedance measurement in patients with esophageal motility disorders. ( 26284688 )
2015
43
Magnetic resonance imaging for simultaneous morphological and functional evaluation of esophageal motility disorders. ( 23689949 )
2014
44
Treatment of esophageal motility disorders based on the chicago classification. ( 25263532 )
2014
45
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. ( 23591282 )
2013
46
Intraoperative assessment of esophagogastric junction distensibility during per oral endoscopic myotomy (POEM) for esophageal motility disorders. ( 22955896 )
2013
47
Surgical treatment for nonspecific esophageal motility disorders. ( 23247887 )
2013
48
Outcomes of laparoscopic Nissen fundoplication in patients with manometric patterns of esophageal motility disorders. ( 23574844 )
2013
49
Reinterpretation of follow-up, high-resolution manometry for esophageal motility disorders based on the updated chicago classification. ( 23710322 )
2013
50
Esophageal motility disorders after bariatric surgery. ( 23852119 )
2013

Variations for Dyskinesia of Esophagus

Expression for Dyskinesia of Esophagus

Search GEO for disease gene expression data for Dyskinesia of Esophagus.

Pathways for Dyskinesia of Esophagus

GO Terms for Dyskinesia of Esophagus

Biological processes related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import across plasma membrane GO:1990573 9.4 ATP12A ATP4A
2 potassium ion import GO:0010107 9.37 ATP12A ATP4A
3 ATP hydrolysis coupled proton transport GO:0015991 9.32 ATP12A ATP4A
4 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
5 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP12A ATP4A
6 cellular potassium ion homeostasis GO:0030007 8.96 ATP12A ATP4A
7 sodium ion export across plasma membrane GO:0036376 8.62 ATP12A ATP4A

Molecular functions related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.33 CENPB TOP1 UBTF
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Dyskinesia of Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....